SCHEMBL20489052

SCHEMBL20489052

CNC(=O)c1cc(C(=O)OC)[nH]n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.74
GAA P10253 1/20 0.50
ALPL P05186 9/20 0.49
MAPT P10636 5/20 0.49
RAB9A P51151 3/20 0.49
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 2/20 0.48
LMNA P02545 1/20 0.48
ABL1 P00519 1/20 0.46
CHEK1 O14757 1/20 0.44
RET P07949 1/20 0.44
PDGFRB P09619 1/20 0.44
PIM1 P11309 1/20 0.44
PDGFRA P16234 1/20 0.44
GSK3B P49841 1/20 0.44
RPS6KA3 P51812 1/20 0.44
LIMK1 P53667 1/20 0.44
CDK5 Q00535 1/20 0.44
TYRO3 Q06418 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20489065 0.86 MAPK1 (0.74) MAPK1GAAALPLMAPTRAB9A
SCHEMBL23185764 0.85 CHEK1 (0.57) MAPK1GAAALPLMAPTRAB9A
SCHEMBL68056 0.85 MAPK1 (1.00) MAPK1GAAALPLMAPTRAB9A
SCHEMBL30614240 0.84 MAPK1 (0.96) MAPK1GAAALPLMAPTRAB9A
SCHEMBL28261041 0.82 MAPK1 (0.79) MAPK1GAAALPLMAPTRAB9A
SCHEMBL1812854 0.82 MAPK1 (0.79) MAPK1GAAALPLMAPTRAB9A
SCHEMBL20488775 0.82 CHEK1 (0.50) MAPK1ALPLCHEK1RETPDGFRB
SCHEMBL30614278 0.81 MAPK1 (0.47) MAPK1GAAALPLMAPTLMNA
SCHEMBL171413 0.78 MAPK1 (0.67) MAPK1GAAALPLMAPTRAB9A
SCHEMBL1814464 0.78 MAPK1 (0.72) MAPK1GAAALPLMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110582485-B Pyrazole derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-13 CN disclosed
EP-3589618-B1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-12-28 EP disclosed
EP-3589618-B1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-12-28 EP disclosed
US-10966961-B2 Pyrazole derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-04-06 US disclosed
US-10966961-B2 Pyrazole derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-04-06 US disclosed
CN-110582485-A Pyrazole derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2019-12-17 CN disclosed
WO-2018158212-A1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10966961-B2 Pyrazole derivatives as bromodomain inhibitors BRD3, BRD4, BRPF3 MAPK1 1170/4885GAA 868/4885ALPL 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.